Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Pierre Henri GabrielleVuong NguyenCatherine P Creuzot GarcherLucia MiguelSocorro AlforjaLaura SararolsRicardo P Casaroli-MaranoJavier Zarranz-VenturaMark GilliesJennifer ArnoldDaniel BarthelmesPublished in: Acta ophthalmologica (2021)
The 24-month treatment outcomes of VEGF inhibitors for mCNV were favourable in this largest series yet reported of predominantly Caucasian eyes in routine clinical practice, with approximately two lines of visual gain and a median of three injections given mostly during the first year. These outcomes are similar to those reported for predominantly Asian eyes. Bevacizumab appeared to be as safe and effective as ranibizumab.
Keyphrases
- vascular endothelial growth factor
- clinical practice
- optical coherence tomography
- african american
- diabetic retinopathy
- endothelial cells
- optic nerve
- electronic health record
- ultrasound guided
- big data
- metastatic colorectal cancer
- metabolic syndrome
- machine learning
- type diabetes
- adipose tissue
- weight loss
- insulin resistance